- ►diabetesjournals.org PJ Larsen, C Fledelius, LB Knudsen, M Tang- … - Diabetes, 2001 - Am Diabetes Assoc Postprandial release of the incretin glucagon-like peptide-1 (GLP-1) has been
suggested to act as an endogenous satiety factor in humans. In rats, however,
the evidence for this is equivocal probably because of very high endogenous ... Cited by 101 - Related articles - BL Direct - All 4 versions
U Ribel, MO Larsen, B Rolin, RD Carr, M … - European journal of pharmacology, 2002 - Elsevier Glucagon-like peptide-1 (GLP-1) is an effective anti-diabetic agent, but its
metabolic instability makes it therapeutically unsuitable. This study
investigated the pharmacodynamics of a long-acting GLP-1 derivative ... Cited by 43 - Related articles - All 4 versions
- ►physiology.org B Rolin, MO Larsen, CF Gotfredsen, CF … - American Journal of Physiology- Endocrinology And …, 2002 - Am Physiological Soc NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1)
derivative designed for once daily administration in humans. NN2211 dose
dependently reduced the glycemic levels in ob/ob mice, with ... Cited by 129 - Related articles - BL Direct - All 4 versions
- ►endojournals.org K Meeran, D O'Shea, CMB Edwards, MD Turton, … - Endocrinology, 1999 - Endocrine Soc Central nervous system glucagon-like peptide-1-(7–36) amide (GLP-1)
administration has been reported to acutely reduce food intake in the rat. We
here report that repeated intracerebroventricular (icv) injection of GLP-1 ... Cited by 136 - Related articles - BL Direct - All 4 versions
- ►endojournals.org M Szayna, ME Doyle, JA Betkey, HW … - Endocrinology, 2000 - Endocrine Soc Exendin-4 is a 39 amino acid peptide produced in the salivary gland of the Gila
monster lizard. It has a 53% amino acid homology to the incretin hormone
glucagon-like peptide-1 (GLP-1). Exendin-4 induces insulin release through ... Cited by 195 - Related articles - BL Direct - All 2 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a
glucose-dependent manner, but its short half-life limits its therapeutic
potential. We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects ... Cited by 94 - Related articles - BL Direct - All 9 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential
interest for the treatment of type 2 diabetes. To evaluate actions of NN2211, a
long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, ... Cited by 174 - Related articles - BL Direct - All 6 versions
HR Davis Jr, DE Mullins, JM Pines, LM Hoos, … - Obesity research, 1998 - ncbi.nlm.nih.gov Glucagon-like peptide (7-36) amide (GLP-1) acutely inhibits food and water
consumption in rats after intracerebroventricular (icv) administration. To
assess the potential for desensitization of these effects, we investigated ... Cited by 29 - Related articles - BL Direct - All 2 versions
M Tang-Christensen, PJ Larsen, R Goke, A … - … Journal of Physiology- Regulatory, Integrative and …, 1996 - Am Physiological Soc 34 other HighWire hosted articles, the first 5 are: This article has been cited
by ... [PDF] [Full Text] [Abstract] , February 1, 2005; 288 (2): E447-E453. Am
J Physiol Endocrinol Metab AD Strader, TP Vahl, RJ Jandacek, SC Woods, DA D' ... Cited by 235 - Related articles - BL Direct - All 3 versions
- ►physiology.org CMB Edwards, SA Stanley, R Davis, AE Brynes … - American Journal of Physiology- Endocrinology And …, 2001 - Am Physiological Soc Exendin-4 is a long-acting potent agonist of the glucagon-like peptide 1 (GLP-1)
receptor and may be useful in the treatment of type 2 diabetes and obesity. We
examined the effects of an intravenous infusion of exendin-4 (0.05 pmol · ... Cited by 230 - Related articles - BL Direct - All 4 versions
